Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cmi.2020.06.003 http://scihub22266oqcxt.onion/10.1016/j.cmi.2020.06.003 32535147!7289730!32535147     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Microbiol+Infect 2020 ; 26 (9): 1259.e5-1259.e7 Nephropedia Template TP {{tp|p=32535147|t=2020. Ibuprofen use and clinical outcomes in COVID-19 patients |pdf=|usr=}}{{32535147}} gab.com Text Ibuprofen use and clinical outcomes in COVID-19 patients JO: Clin Microbiol Infect http://www.kidney.de/pget.php?&tw=1&pmid=32535147 #FOAvip OBJECTIVE: It was recently suggested that ibuprofen might increase the risk for severe and fatal coronavirus disease 2019 (COVID-19) and should therefore be avoided in this patient population. We aimed to evaluate whether ibuprofen use in individuals with COVID-19 was associated with more severe disease, compared with individuals using paracetamol or no antipyretics. METHODS: In a retrospective cohort study of patients with COVID-19 from Shamir Medical Centre, Israel, we monitored any use of ibuprofen from a week before diagnosis of COVID-19 throughout the disease. Primary outcomes were mortality and the need for respiratory support, including oxygen administration and mechanical ventilation. RESULTS: The study included 403 confirmed cases of COVID-19, with a median age of 45 years. Of the entire cohort, 44 patients (11%) needed respiratory support and 12 (3%) died. One hundred and seventy-nine (44%) patients had fever, with 32% using paracetamol and 22% using ibuprofen, for symptom-relief. In the ibuprofen group, 3 (3.4%) patients died, whereas in the non-ibuprofen group, 9 (2.8%) patients died (p 0.95). Nine (10.3%) patients from the ibuprofen group needed respiratory support, compared with 35 (11%) from the non-ibuprofen group (p 1). When compared with exclusive paracetamol users, no differences were observed in mortality rates or the need for respiratory support among patients using ibuprofen. CONCLUSIONS: In this cohort of COVID-19 patients, ibuprofen use was not associated with worse clinical outcomes, compared with paracetamol or no antipyretic. Twit Text FOAVip Ibuprofen use and clinical outcomes in COVID-19 patients ????Clin Microbiol Infect http://www.kidney.de/pget.php?&tw=1&pmid=32535147 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32535147 #FOAvip English Wikipedia <ref>{{Cite pmid|32535147}}</ref> Ibuprofen use and clinical outcomes in COVID-19 patients #MMPMID32535147 Rinott E; Kozer E; Shapira Y; Bar-Haim A; Youngster I Clin Microbiol Infect 2020[Sep]; 26 (9): 1259.e5-1259.e7 PMID32535147show ga OBJECTIVE: It was recently suggested that ibuprofen might increase the risk for severe and fatal coronavirus disease 2019 (COVID-19) and should therefore be avoided in this patient population. We aimed to evaluate whether ibuprofen use in individuals with COVID-19 was associated with more severe disease, compared with individuals using paracetamol or no antipyretics. METHODS: In a retrospective cohort study of patients with COVID-19 from Shamir Medical Centre, Israel, we monitored any use of ibuprofen from a week before diagnosis of COVID-19 throughout the disease. Primary outcomes were mortality and the need for respiratory support, including oxygen administration and mechanical ventilation. RESULTS: The study included 403 confirmed cases of COVID-19, with a median age of 45 years. Of the entire cohort, 44 patients (11%) needed respiratory support and 12 (3%) died. One hundred and seventy-nine (44%) patients had fever, with 32% using paracetamol and 22% using ibuprofen, for symptom-relief. In the ibuprofen group, 3 (3.4%) patients died, whereas in the non-ibuprofen group, 9 (2.8%) patients died (p 0.95). Nine (10.3%) patients from the ibuprofen group needed respiratory support, compared with 35 (11%) from the non-ibuprofen group (p 1). When compared with exclusive paracetamol users, no differences were observed in mortality rates or the need for respiratory support among patients using ibuprofen. CONCLUSIONS: In this cohort of COVID-19 patients, ibuprofen use was not associated with worse clinical outcomes, compared with paracetamol or no antipyretic. |*COVID-19 Drug Treatment[MESH] |Acetaminophen/adverse effects/therapeutic use[MESH] |Adult[MESH] |Antipyretics/adverse effects/therapeutic use[MESH] |COVID-19/*mortality[MESH] |Female[MESH] |Fever/*drug therapy/virology[MESH] |Humans[MESH] |Ibuprofen/adverse effects/*therapeutic use[MESH] |Israel[MESH] |Male[MESH] |Middle Aged[MESH]Ibuprofen use and clinical outcomes in COVID-19 patients (epmc).pdf DeepDyve Pubget Overpricing